Proteomics

Dataset Information

0

Therapeutic targeting glutamine dependence in SWI/SNF-inactivated cancers


ABSTRACT: Alterations in components of the SWI/SNF chromatin-remodeling complex occur in ~20% of all human cancers. For example, ARID1A is mutated in up to 62% of clear cell ovarian carcinoma (OCCC), a disease currently lacking effective therapies. Here we show that ARID1A mutation creates a dependence on glutamine metabolism. SWI/SNF represses glutaminase I (GLS1) and ARID1A inactivation upregulates GLS1. ARID1A inactivation increases glutamine utilization and metabolism through the tricarboxylic acid cycle to support aspartate synthesis. Indeed, glutaminase inhibitor CB-839 suppresses the growth of ARID1A mutant, but not wildtype, OCCCs in both orthotopic and patient-derived xenografts. In addition, glutaminase inhibitor CB-839 synergizes with immune checkpoint blockade anti-PDL1 antibody in a genetic OCCC mouse model driven by conditional Arid1a inactivation. Our data indicate that pharmacological inhibition of glutaminase alone or in combination with immune checkpoint blockade represents a novel therapeutic strategy for cancers involving alterations in the SWI/SNF complex such as ARID1A mutations.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Rugang Zhang  

PROVIDER: MSV000086347 | MassIVE | Wed Oct 21 14:56:00 BST 2020

REPOSITORIES: MassIVE

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2020-10-21 | MSV000086347 | GNPS
2019-02-10 | GSE110449 | GEO
2019-02-10 | GSE110448 | GEO
2024-01-21 | PXD046276 | Pride
2024-01-21 | PXD046275 | Pride
2024-01-21 | PXD046273 | Pride
2020-11-16 | GSE137399 | GEO
2020-11-16 | GSE137397 | GEO
2020-11-16 | GSE137403 | GEO
2024-03-22 | GSE215024 | GEO